Search - tctmd.com

Displaying 21 - 40 of 1502

Sort: Relevancy | Date

CVD Still the Leading Cause of Death and Disease Globally

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

CELEBRATE: Prehospital Platelet Inhibitor Zalunfiban Hits Mark in STEMI

News Daily News

CELEBRATE: Prehospital Platelet Inhibitor Zalunfiban Hits Mark in STEMI

Michael O'Riordan

September 23, 2025

European Experts Provide Advice on Managing CV Effects of COVID-19

News Daily News

European Experts Provide Advice on Managing CV Effects of COVID-19

September 19, 2025

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

News Daily News

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Michael O'Riordan

September 18, 2025

Positive 3-Year Results from FIRE Trial Demonstrate Supraflex Cruz’s Safety and Efficacy in Elderly Heart Attack Patients

News Industry News

Positive 3-Year Results from FIRE Trial Demonstrate Supraflex Cruz’s Safety and Efficacy in Elderly Heart Attack Patients

September 15, 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

News Conference News ESC 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

September 05, 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

News Conference News ESC 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

September 01, 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

News Conference News ESC 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

Michael O'Riordan

August 30, 2025

Evolocumab Gains Expanded Indication for Primary Prevention

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

$Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis$

News Daily News

Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis

August 13, 2025

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

Eclampsia in Pregnancy Sharply Increases Risk of CVD in the Year After Delivery

News Daily News

Eclampsia in Pregnancy Sharply Increases Risk of CVD in the Year After Delivery

July 31, 2025

TCTMD’s Top 10 Most Popular Stories for July 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2025

July 31, 2025

July 2025 Dispatch for the CV Team

News Opinion CV Team Dispatch

July 2025 Dispatch for the CV Team

July 24, 2025

Physical Activity Ebbs, Flows Over a Lifetime but Rarely Rebounds After CVD

News Daily News

Physical Activity Ebbs, Flows Over a Lifetime but Rarely Rebounds After CVD

July 23, 2025

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

News Conference News SCCT 2025

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

Yael L. Maxwell

July 21, 2025

PREVENT Risk Calculator’s Accuracy Varies by Healthcare System, Patient Factors

News Daily News

PREVENT Risk Calculator’s Accuracy Varies by Healthcare System, Patient Factors

Michael O'Riordan

July 18, 2025

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

News Daily News

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

July 16, 2025

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.